
MADE WITH Care














At a Glance

Meet an independently-owned developer and manufacturer of Finished Dosage Forms (FDF) and Active Pharmaceutical Ingredients (API).

From its headquarters in Barcelona, Spain, Medichem has grown into **one of the largest worldwide manufacturers of Generics and Chlorhexidine in the pharmaceutical industry**.

Over the years, Medichem has been **at the forefront of innovation** and as such has developed 70 value-added and high-quality drug products.





People First

OUR GREATEST ASSET


Without the commitment of our 480 employees around the world, Medichem wouldn't be one of the worldwide leading manufacturers in the pharmaceutical industry.

Empowering team members to deliver results at this level requires ongoing investment in our workforce, from recruiting to training to quality-of-life considerations. This is how Medichem supports team members to go above and beyond in their daily work.




A SIMPLE PLEDGE

Medichem team members have many different backgrounds and talents, yet we share the same perspective: that quality comes first and special care needs to be given to every step of development and manufacturing and during each customer interaction.



Specialised Generics



Medichem develops and manufactures cGMP Active Pharmaceutical Ingredients (API), including Highly Potent APIs (HPAPI) and Finished Dosage Forms (FDF).

Over the past few years, Medichem has focused on APIs and FDFs with particular technological barriers, creating 70 value-added products aimed at **various therapeutic areas**.

Central Nervous System

FINISHED DOSAGE FORMS

More recently, Medichem has turned the spotlight on FDF, focusing on innovative formulations of injectables and solid oral drugs.



SOLID ORAL DOSAGE

- Capsules
- Tablets
- Film-coated tablets
- New! Multiparticulates




ORAL SOLUTIONS

Oral Solution in bottle

STERILE FORMS

- Nebulizer solution in plastic ampoule blow-fill-seal
- Powder for solution for injection or infusion in glass vial
- Pre-filled syringe
- Solution for injection or infusion in plastic bags




MADE WITH CARE



Unstoppable Chlorhexidine

Medichem started manufacturing chlorhexidine salts back in 1985. Since then, we have become one of the world's largest manufacturers while enlarging our portfolio and expanding into new markets.





Despite the numerous applications for chlorhexidine, we manufacture it using the same quality system we apply to Active Pharmaceutical Ingredients.



Medichem CDG* is listed under article 95 of the EU Biocidal Products Regulation (BPR).



Successful FDA inspections of our Spanish site since 1999.



First manufacturer to obtain the CEP back in 1998.




Collaboration in the development of the CDG* monograph.

Innovation and Excellence

R&D is the root of Medichem's strategy and success. Highly-qualified personnel engage daily in technically challenging projects, with the objective of developing high-quality value-added drug products. Medichem has extensive and proven know-how in solid and injectable dosage forms; moreover, we have HPAPI capabilities that enable us to develop breakthrough products.

From the very first step, every development program is designed to meet all regulatory requirements, to the highest standard of quality, with set goals and achievement monitoring.




O.PRIVITERA




Safety, Quality and Delivery. In that order

When managing multi-purpose production lines, our primary goal is to maintain a safe workplace for our team to be able to manufacture to the highest quality standards of the pharmaceutical industry, while ensuring a timely delivery to our clients.

VERTICALLY-INTEGRATED: FROM INTERMEDIATES TO FDF



STATE-OF-THE-ART TECHNOLOGIES








Essential Partnerships

Medichem has developed a solid base of international clients and delivers products to more than 70 countries, including the United States and within Europe, while consolidating alliances with strategic partners.

To better answer our global growth and customer requests, last year Medichem opened an **office in the USA** in addition to our **headquarters in Barcelona**, Spain, and our **commercial office in China**.



Regulatory Affairs

Requests for **scientific data that supports the quality, safety and efficacy of drugs** from Regulatory Authorities all over the world are addressed on a daily basis by Medichem's regulatory team. These key staff members have long-standing expertise dealing with diverse requirement-based scenarios across the world, with a focus on Europe and the USA.

In our team you will find **personalized, agile support** to ensure access to any market in a rapid manner, supported by reliable, scientifically-driven documentation. We provide the best possible grounds for success regardless of how hard to reach it may seem. Nothing is out of reach for us.

LONG-STANDING EXPERTISE



...submitted to date to Regulatory Agencies around the globe



VALUE-ADDED SOLUTIONS

Be first-to-market

INTELLECTUAL PROPERTY is a key strategic asset at Medichem, which fully supports and protects the business interests of Medichem and its clients. Thanks to its two strategic facilities in Malta, Medichem can provide clients with first-to-market opportunities. While in full respect of intellectual property rights, the country's unique patent situation allows **generic drugs to be produced in advance of patent expiry to ensure medicines are available from the first day after their expiration date in any given market**.


Products are selected with an advantageous patent strategy, ensuring the freedom to operate and at the same time protecting Medichem's innovative ideas with a global patent portfolio. Medichem's experienced IP team employs multiple IP approaches creating both long- and short-term competitive advantages.

MALTA

Contract Services

Medichem offers a wide range of contract services, whether that be the manufacturing of APIs (including HPAPI) or the manufacturing and packaging of the finished dosage form, testing or release services.

TAILOR-MADE SOLUTIONS



The strategic planning and location in Malta of Medichem and Combino Pharm allow the launch of new products to the market, from the first day after the expiration date of the patent. Being the first to launch is without a doubt key to achieving optimal market penetration.

RELIABILITY




Reliability, a company value built over 46 years

Medichem consolidated its business model between 1972 and 1985. During this time, a generic company earned the first "Paragraph IV" patent certification from the US regulatory agency, the FDA, using the API produced by Medichem. **This paved the way for Medichem's market expansion in the USA and globally**.









MEDICHEM S.A.

Carrer de Fructuós Gelabert, 6 08970 Sant Joan Despí, Barcelona - SPAIN Tel: +34 93 477 64 40

MEDICHEM USA, LLC

Hoboken Business Center 50 Harrison Street, Suite 217 Hoboken, NJ 07030 - USA Tel: +1 201 420 1800

MEDICHEM, NRC

Nanjing, PRC Tel: +86-18602518443

MEDICHEM MANUFACTURING (MALTA) LTD. Hal Far (BBG)

MALTA

MEDICHEM, S.A. - MANUFACTURING

Celrà (Girona) SPAIN

COMBINO PHARM (MALTA) LTD.

Hal Far (BBG) MALTA

www.medichem.es

This brochure is for informative purposes only. Even though Medichem has used good faith efforts to provide accurate and complete information, Medichem makes no warranties or representation of any kind, whether express or implied, as to the nature, accuracy, completeness of any information provided herein, or non-infringement of intellectual property rights, merchantability and/or fitness for a particular use of Medichem's products and Medichem does not assume any liability resulting thereof.